Related Experiment Video
Updated: May 10, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Inflammatory phenotypes underlying uncontrolled childhood asthma despite inhaled corticosteroid treatment: rationale
Insights
This study identifies inflammatory phenotypes in childhood asthma to personalize treatment. Identifying these distinct patterns in children can improve asthma management and drug development.
Area of Science:
- Pediatric pulmonology and allergy research.
- Translational medicine and biomarker discovery.
Background:
- Childhood asthma diagnosis encompasses diverse mechanisms leading to similar symptoms but requiring tailored treatments.
- Underlying inflammatory patterns significantly influence treatment response in pediatric asthma patients.
Purpose of the Study:
- To identify distinct inflammatory phenotypes in children with asthma using peripheral blood and exhaled air measures.
- To differentiate between uncontrolled and controlled childhood asthma despite inhaled corticosteroid (ICS) use.
Main Methods:
- The PACMAN2 study is a nested, case-control follow-up of the PACMAN cohort, focusing on detailed phenotyping.
- Participants (children aged ≥ 8 years) underwent clinical follow-up visits assessing symptoms, medication adherence, and environmental factors.
- Measures included pulmonary function, exhaled nitric oxide and volatile organic compounds, and inflammatory markers in blood and plasma.
Main Results:
- Comparative and cluster analyses were employed to identify differentiating markers.
- The study aimed to distinguish children with uncontrolled asthma (cases) from those with controlled asthma (controls) on ICS therapy.
Conclusions:
- Identifying specific inflammatory phenotypes in pediatric asthma is crucial for personalized anti-inflammatory therapy.
- This research can lead to novel therapeutic targets and improved clinical trial designs for pediatric asthma treatments.
Background:
The diagnosis of childhood asthma covers a broad spectrum of pathological mechanisms that can lead to similarly presenting clinical symptoms, but may nonetheless require different treatment approaches. Distinct underlying inflammatory patterns are thought to influence responsiveness to standard asthma medication.
Methods/Design:
The purpose of the PACMAN2 study is to identify inflammatory phenotypes that can discriminate uncontrolled childhood asthma from controlled childhood asthma by measures in peripheral blood and exhaled air. PACMAN2 is a nested, case-control follow-up study to the ongoing pharmacy-based "Pharmacogenetics of Asthma medication in Children: Medication with Anti-inflammatory effects" (PACMAN) study. The original PACMAN cohort consists of children aged 4-12 years with reported use of asthma medication. The PACMAN2 study will be conducted within the larger PACMAN cohort, and will focus on detailed phenotyping of a subset of the PACMAN children. The selected participants will be invited to a follow-up visit in a clinical setting at least six months after their baseline visit based on their adherence to usage of inhaled corticosteroids, their asthma symptoms in the past year, and their age (≥ 8 years). During the follow-up visit, current and long-term asthma symptoms, medication use, environmental factors, medication adherence and levels of exhaled nitric oxide will be reassessed. The following measures will also be examined: pulmonary function, exhaled volatile organic compounds, as well as inflammatory markers in peripheral blood and blood plasma. Comparative analysis and cluster-analyses will be used to identify markers that differentiate children with uncontrolled asthma despite their use of inhaled corticosteroids (ICS) (cases) from children whose asthma is controlled by the use of ICS (controls).
Discussion:
Asthmatic children with distinct inflammatory phenotypes may respond differently to anti-inflammatory therapy. Therefore, by identifying inflammatory phenotypes in children with the PACMAN2 study, we may greatly impact future personalised treatment strategies, uncover new leads for therapeutic targets and improve the design of future clinical studies in the assessment of the efficacy of novel therapeutics.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:13Asthma III: Clinical Manifestations